Click here to get full coverage on Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView

Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH  TradingView

Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView

Click here to get full coverage on DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch  Stocktwits

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits

Click here to get full coverage on Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - simplywall.st

Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial  simplywall.st

Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - simplywall.st

Click here to get full coverage on Dianthus launches Phase 3 study of claseprubart in rare muscle disease - Stock Titan

Dianthus launches Phase 3 study of claseprubart in rare muscle disease  Stock Titan

Dianthus launches Phase 3 study of claseprubart in rare muscle disease - Stock Titan

Click here to get full coverage on (DNTH) Risk Channels and Responsive Allocation - Stock Traders Daily

(DNTH) Risk Channels and Responsive Allocation  Stock Traders Daily

(DNTH) Risk Channels and Responsive Allocation - Stock Traders Daily

Click here to get full coverage on Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative - Yahoo Finance

Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative  Yahoo Finance

Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com

Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark  marketscreener.com

Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com

Click here to get full coverage on DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - Yahoo Finance

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?  Yahoo Finance

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance

Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier  Yahoo Finance

Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance

Click here to get full coverage on Dianthus drops as Sanofi halts trial for peer drug (DNTH) - Seeking Alpha

Dianthus drops as Sanofi halts trial for peer drug (DNTH)  Seeking Alpha

Dianthus drops as Sanofi halts trial for peer drug (DNTH) - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2500 Value Benchmark - marketscreener.com

Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2500 Value Benchmark  marketscreener.com

Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2500 Value Benchmark - marketscreener.com

Click here to get full coverage on Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline - Yahoo Finance

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline  Yahoo Finance

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline - Yahoo Finance

Click here to get full coverage on $DNTH stock is down 15% today. Here's what we see in our data. - Quiver Quantitative

$DNTH stock is down 15% today. Here's what we see in our data.  Quiver Quantitative

$DNTH stock is down 15% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance

Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision  Yahoo Finance

Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance

Click here to get full coverage on Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?  Yahoo Finance

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Click here to get full coverage on DNTH - Dianthus Therapeutics Inc Stock Price and Quote - Finviz

DNTH - Dianthus Therapeutics Inc Stock Price and Quote  Finviz

DNTH - Dianthus Therapeutics Inc Stock Price and Quote - Finviz

Click here to get full coverage on Evaluating Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance

Evaluating Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains  Yahoo Finance

Evaluating Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance

Click here to get full coverage on Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise - Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise  Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics (DNTH) Is Down 10.0% After FDA Eases Claseprubart Trials And Grants Orphan Status - simplywall.st

Dianthus Therapeutics (DNTH) Is Down 10.0% After FDA Eases Claseprubart Trials And Grants Orphan Status  simplywall.st

Dianthus Therapeutics (DNTH) Is Down 10.0% After FDA Eases Claseprubart Trials And Grants Orphan Status - simplywall.st

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued - simplywall.st

Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued  simplywall.st

Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued - simplywall.st

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on DNTH Technical Analysis | Trend, Signals & Chart Patterns - ChartMill

DNTH Technical Analysis | Trend, Signals & Chart Patterns  ChartMill

DNTH Technical Analysis | Trend, Signals & Chart Patterns - ChartMill

Click here to get full coverage on Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Yahoo Finance

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)  Yahoo Finance

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Yahoo Finance

Click here to get full coverage on DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results  Stocktwits

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits

Click here to get full coverage on Leads Biolabs and DNTH initiate trial of LBL-047 in SLE - Clinical Trials Arena

Leads Biolabs and DNTH initiate trial of LBL-047 in SLE  Clinical Trials Arena

Leads Biolabs and DNTH initiate trial of LBL-047 in SLE - Clinical Trials Arena

Click here to get full coverage on Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan

Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares  Stock Titan

Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan

Click here to get full coverage on [144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan

[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing  Stock Titan

[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan

Click here to get full coverage on Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - Yahoo Finance

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000  Yahoo Finance

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - Yahoo Finance

Click here to get full coverage on Biotech Dianthus prices $625M deal to advance autoimmune drugs - Stock Titan

Biotech Dianthus prices $625M deal to advance autoimmune drugs  Stock Titan

Biotech Dianthus prices $625M deal to advance autoimmune drugs - Stock Titan

Click here to get full coverage on Why is Dianthus Therapeutics stock plunging today? - Investing.com

Why is Dianthus Therapeutics stock plunging today?  Investing.com

Why is Dianthus Therapeutics stock plunging today? - Investing.com

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Medpace Holdings (MEDP) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Medpace Holdings (MEDP)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Medpace Holdings (MEDP) - The Globe and Mail

Click here to get full coverage on Dianthus CEO to field investor questions at TD Cowen health summit - Stock Titan

Dianthus CEO to field investor questions at TD Cowen health summit  Stock Titan

Dianthus CEO to field investor questions at TD Cowen health summit - Stock Titan

Click here to get full coverage on DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth - TradingView

DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth  TradingView

DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth - TradingView

Click here to get full coverage on Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - The Motley Fool

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000  The Motley Fool

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - The Motley Fool

Click here to get full coverage on Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH) - Seeking Alpha

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH)  Seeking Alpha

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH) - Seeking Alpha

Click here to get full coverage on Artia Global Partners LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Artia Global Partners LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH  MarketBeat

Artia Global Partners LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Click here to get full coverage on Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135 - Moomoo

Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135  Moomoo

Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135 - Moomoo

Click here to get full coverage on Avidity Partners Management LP Sells 1,100,000 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Avidity Partners Management LP Sells 1,100,000 Shares of Dianthus Therapeutics, Inc. $DNTH  MarketBeat

Avidity Partners Management LP Sells 1,100,000 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Click here to get full coverage on Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating - Moomoo

Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating  Moomoo

Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating - Moomoo

Click here to get full coverage on Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism - Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism  Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism - Yahoo Finance

Click here to get full coverage on Dianthus gives 8 new employees stock options at $84.56 a share - Stock Titan

Dianthus gives 8 new employees stock options at $84.56 a share  Stock Titan

Dianthus gives 8 new employees stock options at $84.56 a share - Stock Titan

Click here to get full coverage on How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart - Yahoo Finance

How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart  Yahoo Finance

How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart - Yahoo Finance

Click here to get full coverage on Biotech Dianthus hands new hires 60,000 stock options at $89.45 - Stock Titan

Biotech Dianthus hands new hires 60,000 stock options at $89.45  Stock Titan

Biotech Dianthus hands new hires 60,000 stock options at $89.45 - Stock Titan

Click here to get full coverage on Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM) - The Globe and Mail

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)  The Globe and Mail

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM) - The Globe and Mail

Click here to get full coverage on Six new Dianthus hires get options to buy 135,000 shares - Stock Titan

Six new Dianthus hires get options to buy 135,000 shares  Stock Titan

Six new Dianthus hires get options to buy 135,000 shares - Stock Titan

Click here to get full coverage on Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH) - Seeking Alpha

Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH)  Seeking Alpha

Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH) - Seeking Alpha

Click here to get full coverage on (DNTH) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(DNTH) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(DNTH) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Early GO decision lets Dianthus cut CIDP trial, keep 300mg dose - Stock Titan

Early GO decision lets Dianthus cut CIDP trial, keep 300mg dose  Stock Titan

Early GO decision lets Dianthus cut CIDP trial, keep 300mg dose - Stock Titan

Click here to get full coverage on DNTH (NASDAQ) director files Form 144 to sell 26,530 shares - Stock Titan

DNTH (NASDAQ) director files Form 144 to sell 26,530 shares  Stock Titan

DNTH (NASDAQ) director files Form 144 to sell 26,530 shares - Stock Titan

Click here to get full coverage on $DNTH stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$DNTH stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$DNTH stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Why Is Dianthus Therapeutics Stock Trading Higher On Friday? - Benzinga

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?  Benzinga

Why Is Dianthus Therapeutics Stock Trading Higher On Friday? - Benzinga

Click here to get full coverage on $DNTH stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

$DNTH stock is up 13% today. Here's what we see in our data.  Quiver Quantitative

$DNTH stock is up 13% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Liquidity Mapping Around (DNTH) Price Events - Stock Traders Daily

Liquidity Mapping Around (DNTH) Price Events  Stock Traders Daily

Liquidity Mapping Around (DNTH) Price Events - Stock Traders Daily

Click here to get full coverage on DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution - TradingView

DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution  TradingView

DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution - TradingView

Click here to get full coverage on Stifel reiterates Dianthus Therapeutics stock Buy on rival setback - Investing.com

Stifel reiterates Dianthus Therapeutics stock Buy on rival setback  Investing.com

Stifel reiterates Dianthus Therapeutics stock Buy on rival setback - Investing.com

Click here to get full coverage on Dianthus Therapeutics (DNTH) EVP sells 26,530 shares after option exercises - Stock Titan

Dianthus Therapeutics (DNTH) EVP sells 26,530 shares after option exercises  Stock Titan

Dianthus Therapeutics (DNTH) EVP sells 26,530 shares after option exercises - Stock Titan

Click here to get full coverage on Understanding Momentum Shifts in (DNTH) - Stock Traders Daily

Understanding Momentum Shifts in (DNTH)  Stock Traders Daily

Understanding Momentum Shifts in (DNTH) - Stock Traders Daily

Click here to get full coverage on Autoimmune bet aims to reshape care for 150,000 gMG, CIDP, MMN - Stock Titan

Autoimmune bet aims to reshape care for 150,000 gMG, CIDP, MMN  Stock Titan

Autoimmune bet aims to reshape care for 150,000 gMG, CIDP, MMN - Stock Titan

Click here to get full coverage on Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock - Quiver Quantitative

Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock  Quiver Quantitative

Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients - TradingView

Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients  TradingView

Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients - TradingView

Click here to get full coverage on Guggenheim reiterates Dianthus stock rating citing potency edge - Investing.com

Guggenheim reiterates Dianthus stock rating citing potency edge  Investing.com

Guggenheim reiterates Dianthus stock rating citing potency edge - Investing.com

Click here to get full coverage on Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit - Investor's Business Daily

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit  Investor's Business Daily

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit - Investor's Business Daily

Click here to get full coverage on DNTH stock clocks best day in over 3 months on strong nerve disorder study results - MSN

DNTH stock clocks best day in over 3 months on strong nerve disorder study results  MSN

DNTH stock clocks best day in over 3 months on strong nerve disorder study results - MSN

Click here to get full coverage on Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions - Seeking Alpha

Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions  Seeking Alpha

Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics to Participate in Two Investor Conferences - Yahoo Finance

Dianthus Therapeutics to Participate in Two Investor Conferences  Yahoo Finance

DNTH

Price Chart

Key Statistics

Technicals

About DNTH

Latest News

Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits

Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - simplywall.st

Advanced Charts

Top Gainers

Top Losers